

Fusidic Acid Cream

Active ingredient	Fusidic acid
Strength	20 mg/g
Therapeutic indication	Treatment of non-severe, superficial, non-extensive, primary skin infections caused by microorganisms that are sensitive to fusidic acid, especially of infections caused by Staphylococcus. Primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma.
Reference (originator) product	Fucidin cream 20 mg/g
Pharmaceutical form	Cream
Pack Size	15 g 30 g
Packaging	Aluminium tube with a HDPE cap
Finished product manufacturer	Basic Pharma Manufacturing – The Netherlands
Biostudy	No
Clinical trial	Yes
Regulatory status	Dossier: e-CTD DCP: RMS NL; several CMSs Registered in 2012
Shelf-life	2 years
Batch size	750 kg

For any other information please contact:

Business Development
bd@basicpharma.nl

Burgemeester Lemmensstraat 352
 6163 JT Geleen
 Netherlands

+31(0)88 255 40 10
 basicpharma.nl